Abstract
Obesity is dramatically increasing virtually worldwide, which has been linked to the rising prevalence of metabolic syndrome. Excess fat accumulation causes severe alterations in adipose tissue function. Actually, adipose tissue is now recognized as a major endocrine and secretory organ that releases a wide variety of signaling molecules (hormones, growth factors, cytokines, chemokines, etc.), the adipokines, which play central roles in the regulation of energy metabolism and homeostasis, immunity and inflammation. In addition, adipose tissue is no longer regarded as a passive lipid storage site but as a highly dynamic energy depot which stores excess energy during periods of positive energy balance and mobilizes it in periods of nutrient deficiency in a tightly regulated manner. Altered lipid release and adipokine production and signaling, as occurs in obesity, are linked to insulin resistance and the associated comorbidities of metabolic syndrome (dyslipidemia, hypertension), which confer an increased risk for the development of type 2 diabetes and cardiovascular disease. Here we summarize current knowledge on adipose tissue and review the contribution of novel techniques and experimental approaches in adipobiology to the identification of novel biomarkers and potential targets for dietary or pharmacological intervention to prevent and treat adipose tissue-associated diseases.
Keywords: Adipose tissue, adipocytes, adipokines, adipoproteomics, diet, lipid metabolism, metabolic syndrome, obesity.
Current Vascular Pharmacology
Title:Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome
Volume: 11 Issue: 6
Author(s): Maria M. Malagon, Alberto Díaz-Ruiz, Rocio Guzman-Ruiz, Yolanda Jimenez-Gomez, Natalia R. Moreno, Socorro Garcia-Navarro, Rafael Vazquez-Martinez and Juan R. Peinado
Affiliation:
Keywords: Adipose tissue, adipocytes, adipokines, adipoproteomics, diet, lipid metabolism, metabolic syndrome, obesity.
Abstract: Obesity is dramatically increasing virtually worldwide, which has been linked to the rising prevalence of metabolic syndrome. Excess fat accumulation causes severe alterations in adipose tissue function. Actually, adipose tissue is now recognized as a major endocrine and secretory organ that releases a wide variety of signaling molecules (hormones, growth factors, cytokines, chemokines, etc.), the adipokines, which play central roles in the regulation of energy metabolism and homeostasis, immunity and inflammation. In addition, adipose tissue is no longer regarded as a passive lipid storage site but as a highly dynamic energy depot which stores excess energy during periods of positive energy balance and mobilizes it in periods of nutrient deficiency in a tightly regulated manner. Altered lipid release and adipokine production and signaling, as occurs in obesity, are linked to insulin resistance and the associated comorbidities of metabolic syndrome (dyslipidemia, hypertension), which confer an increased risk for the development of type 2 diabetes and cardiovascular disease. Here we summarize current knowledge on adipose tissue and review the contribution of novel techniques and experimental approaches in adipobiology to the identification of novel biomarkers and potential targets for dietary or pharmacological intervention to prevent and treat adipose tissue-associated diseases.
Export Options
About this article
Cite this article as:
Malagon M. Maria, Díaz-Ruiz Alberto, Guzman-Ruiz Rocio, Jimenez-Gomez Yolanda, Moreno R. Natalia, Garcia-Navarro Socorro, Vazquez-Martinez Rafael and Peinado R. Juan, Adipobiology for Novel Therapeutic Approaches in Metabolic Syndrome, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/15701611113116660170
DOI https://dx.doi.org/10.2174/15701611113116660170 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aliskiren: A New Drug for an Old Problem
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiac Remodeling and Exercise Training in Hypertension
Current Hypertension Reviews Colchicine in Coronary Artery Disease: An Old Acquaintance in New Attire?
Current Medicinal Chemistry The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry Carotid Intima Media-thickness and Genes Involved in Lipid Metabolism in Diabetic Patients using Statins – a Pathway Toward Personalized Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Epigenetics in Vascular Disease – Therapeutic Potential of New Agents
Current Vascular Pharmacology Formulation and Evaluation of Non-Effervescent Floating Tablets of Losartan Potassium
Current Drug Delivery Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Dietary Management of Gestational Diabetes Mellitus
Current Nutrition & Food Science Late versus Early Onset Depression in Elderly Patients: Vascular Risk and Cognitive Impairment
Current Aging Science Antiviral Drug Discovery Targeting to Viral Proteases
Current Pharmaceutical Design Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases
Current Pharmaceutical Design Comparative Effect of Telmisartan vs Lisinopril on Blood Pressure in Patients of Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets The Emerging Role of microRNA in Stroke
Current Topics in Medicinal Chemistry Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer
Current Drug Targets The Reno-Protective Effect of the Dual Blockade of the Renin Angiotensin System (RAS)
Current Pharmaceutical Design Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism